Investor Relations

Financial Tear Sheet

Financial Tear Sheet

Corporate Profile

Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. The Company’s objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. The Company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome.

Stock Quote

Price Change
Volume % Change  
Intraday High 52 Week High
Intraday Low 52 Week Low
Today's Open Currency US Dollar
Previous Close Exchange

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title
Millendo Therapeutics, Inc. to Present at the 18th Annual Needham Healthcare Conference
Printer Friendly Version
Millendo Reports Full Year 2018 Operating and Financial Results
Printer Friendly Version
Millendo Therapeutics Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome
Printer Friendly Version

SEC Filings

Filing date Form

Primary IR Contact

Stephanie Ascher
Phone: 212-362-1200

Stock Chart